These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 24938173)

  • 1. Polybacterial human disease: the ills of social networking.
    Short FL; Murdoch SL; Ryan RP
    Trends Microbiol; 2014 Sep; 22(9):508-16. PubMed ID: 24938173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacterial signaling as an antimicrobial target.
    Ellermann M; Sperandio V
    Curr Opin Microbiol; 2020 Oct; 57():78-86. PubMed ID: 32916624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of synergy in polymicrobial infections.
    Murray JL; Connell JL; Stacy A; Turner KH; Whiteley M
    J Microbiol; 2014 Mar; 52(3):188-99. PubMed ID: 24585050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-virulence strategies to combat bacteria-mediated disease.
    Rasko DA; Sperandio V
    Nat Rev Drug Discov; 2010 Feb; 9(2):117-28. PubMed ID: 20081869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between the microbiota and pathogenic bacteria in the gut.
    Bäumler AJ; Sperandio V
    Nature; 2016 Jul; 535(7610):85-93. PubMed ID: 27383983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel approaches to bacterial infection therapy by interfering with cell-to-cell signaling.
    Rasko DA; Sperandio V
    Curr Protoc Microbiol; 2009 Feb; Chapter 17():Unit17.3. PubMed ID: 19235150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-virulence Strategies to Target Bacterial Infections.
    Mühlen S; Dersch P
    Curr Top Microbiol Immunol; 2016; 398():147-183. PubMed ID: 26942418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible drugs for the treatment of bacterial infections in the future: anti-virulence drugs.
    Ogawara H
    J Antibiot (Tokyo); 2021 Jan; 74(1):24-41. PubMed ID: 32647212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting virulence for antimicrobial chemotherapy.
    Lee YM; Almqvist F; Hultgren SJ
    Curr Opin Pharmacol; 2003 Oct; 3(5):513-9. PubMed ID: 14559097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving the treatment of musculoskeletal infections with molecular diagnostics.
    Tarkin IS; Dunman PM; Garvin KL
    Clin Orthop Relat Res; 2005 Aug; (437):83-8. PubMed ID: 16056030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parallels among natural and synthetically modified quorum-quenching strategies as convoy to future therapy.
    Gupta K; Daroch P; Harjai K; Chhibber S
    Microbiology (Reading); 2019 Dec; 165(12):1265-1281. PubMed ID: 31264956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of interspecies signaling for virulence of bacterial and fungal pathogens.
    Holcombe LJ; O'Gara F; Morrissey JP
    Future Microbiol; 2011 Jul; 6(7):799-817. PubMed ID: 21797692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of Drug Resistance in Bacteria.
    Waclaw B
    Adv Exp Med Biol; 2016; 915():49-67. PubMed ID: 27193537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galleria mellonella as an infection model: an in-depth look at why it works and practical considerations for successful application.
    Pereira MF; Rossi CC; da Silva GC; Rosa JN; Bazzolli DMS
    Pathog Dis; 2020 Nov; 78(8):. PubMed ID: 32960263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of polybacterial communities in patients with postoperative, posttraumatic, and endogenous endophthalmitis through 16S rRNA gene libraries.
    Jayasudha R; Narendran V; Manikandan P; Prabagaran SR
    J Clin Microbiol; 2014 May; 52(5):1459-66. PubMed ID: 24574297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The biology and future prospects of antivirulence therapies.
    Cegelski L; Marshall GR; Eldridge GR; Hultgren SJ
    Nat Rev Microbiol; 2008 Jan; 6(1):17-27. PubMed ID: 18079741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Underestimated collateral effects of antibiotic therapy in prosthesis-associated bacterial infections.
    Baldassarri L; Montanaro L; Creti R; Arciola CR
    Int J Artif Organs; 2007 Sep; 30(9):786-91. PubMed ID: 17918123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotic resistance in bacteria.
    Amyes SG; Gemmell CG
    J Med Microbiol; 1992 Jan; 36(1):4-29. PubMed ID: 1731057
    [No Abstract]   [Full Text] [Related]  

  • 19. Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6.
    DeCory HH; Sanfilippo CM; Proskin HM; Blondeau JM
    PLoS One; 2020; 15(8):e0237603. PubMed ID: 32841261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting virulence not viability in the search for future antibacterials.
    Heras B; Scanlon MJ; Martin JL
    Br J Clin Pharmacol; 2015 Feb; 79(2):208-15. PubMed ID: 24552512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.